Abstract: The present invention provides composition and methods for the treatment of cancer or infectious diseases in a human. The invention includes the generation and administration of gamma delta T cells that express chimeric antigen receptors (CARs) comprising an antigen binding domain, a hinge domain, a transmembrane domain, a costimulatory signalling domain with the inclusion or not of a CD3 zeta signalling domain. Expression of CAR sequence omitting the CD3 zeta signalling domain in gamma delta T cells, provides for a CAR-T therapy in vivo, which will effect cytolysis only on target cells providing ligands for activation of the gamma delta T cell receptor (TCR).

Abstract: The present invention provides a T cell which expresses a gamma-delta T cell receptor (TCR) and a chimeric antigen receptor (CAR), wherein the CAR comprises: an antigen binding domain; a transmembrane domain; and a co-stimulatory intracellular signalling domain; wherein the intracellular signalling domain provides a co-stimulatory signal to the T cell following binding of antigen to the antigen binding domain.

Abstract: Disclosed herein are methods of treating an EBV-LPD (Epstein-Barr Virus-associated lymphoproliferative disorder) in a human patient who has failed combination chemotherapy to treat the EBV-LPD and/or radiation therapy to treat the EBV-LPD, comprising administering to the human patient a population of allogeneic T cells comprising EBV-specific T cells.

Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.

Abstract: A pure platelet-rich plasma (P-PRP) composition as an alternative to conventional antibiotic treatment of subclinical mastitis caused by Gram-positive bacteria in bovine including five live platelets and leukocytes, an anticoagulant, and an activating substance.

Abstract: A method for isolating and processing bone marrow derived stem cells, including the steps of: (a) collecting a biological sample containing adherent bone marrow stem cells in a receptacle with interior walls coated with a cell-adherent substrate; (b) incubating the bone marrow cells on the adherent substrate so that a layer of adherent bone marrow stem cells adheres to the substrate; (c) washing any non-adherent cells from the substrate; and (d) collecting the bone marrow stem cell layer. Isolation kits and use of bone marrow cells harvested for cell therapies are also described.

Abstract: Embodiments of the disclosure concern compositions and methods of use related to particular c-kit+ mesenchymal cells, including cardiac stem cells, obtained from a pediatric or neonatal individual. In specific embodiments, the cells, or conditioned medium or partial or total secretomes thereof, are provided in an effective amount to an individual in need thereof.

Abstract: ECM based compositions including amniotic membrane and methods for employing same to treat cardiovascular disorders.

Abstract: Provided herein are methods of making a cell growth scaffold from adipose tissue, cell growth scaffolds having low lipid content and methods of using the cell growth scaffold.

Abstract: The present invention provides marine lecithin preparations including a marine lecithin and one or more exogenous antioxidants. Also provided are a nutritional, pharmaceutical, or nutraceutical composition or a functional or medical food including the marine lecithin preparations. Also provided are processes for making the marine lecithin preparations. Also provided are methods of treating or preventing a disease or disorder, the methods including administering to a subject a therapeutically effective amount of the marine lecithin preparations. Also provided are methods of decreasing an oxidation status of a composition administrated to a subject in need of marine lecithin, the methods including administration of the composition and co-administration of an effective amount of the marine lecithin preparations to the subject in need of marine lecithin.

Abstract: The present disclosure provides methods and treatment regimens for treating ulcerative colitis in a subject in need thereof. In particular, the methods described herein comprise treating a subject in need thereof with a treatment regimen comprising the administration of a pharmaceutical composition comprising live non-pathogenic fecal bacteria for at least 8 weeks and at least three times per week. In an aspect, the subject in need thereof exhibits a Mayo endoscopy score of 3 or lower. In some aspects, the subject in need thereof has no concomitant corticosteroid use during said method and has no corticosteroid use immediately prior to commencing said method.

Abstract: The application relates to methods based on modulating mammalian intestinal microbiota and related probiotic and prebiotic compositions. Specifically, the application relates to the use of novel bacterial genera Ileibacterium and Dubosiella, including their species I. valens (I. valens) and Dubosiella newyorkensis (D. newy), respectively, and closely related OTUs within the family Erysipelotrichaceae that resemble either Ileibacterium spp. or Dubosiella spp. with 90% 16S rRNA sequence identity, for modulating weight and intestinal inflammation and immunity (including modulating intestinal immune gene expression such as, e.g., modulating expression of ROR?T, IL-17A, IL-17F, RegIII?, Relm?, and Def?), as well as for treatment and diagnosis of (i) obesity and related conditions such as metabolic syndrome and diabetes mellitus; (ii) allergic and autoimmune diseases, and (iii) gastrointestinal disorders (such as, e.g., inflammatory bowel disease (IBD), ulcerative colitis, Crohn's disease, and celiac disease).

Abstract: The present invention relates to a functional composition for preventing, alleviating or treating bone disease and lipid-related metabolic disease, and more particularly to a composition which comprises a combination of probiotics and a vitamin complex, which is capable of effectively preventing, alleviating or treating bone disease, obesity and lipid-related metabolic disease by synergistic effects on antioxidant activity, a reduction in blood lipid levels and the promotion of in vivo absorption of calcium and iron.

Abstract: The present invention relates to the use of antibiotics with specific therapeutic activities combined with the simultaneous use of lactobacilli and/or bifidobacteria having a non-transferable antibiotic resistance and with the same therapeutic indication as said antibiotics.

Abstract: The present invention relates to a pharmaceutical composition and a food composition containing Portulaca grandiflora Hook. extract or a fraction thereof as an active ingredient for preventing, treating or ameliorating neuroinflammation or neuro-degenerative diseases. The Portulaca grandiflora Hook. extract or a fraction thereof according to the present invention is derived from a natural product which has been in use as a natural medicinal ingredient, and as such, has no side effects and inhibits expression of NO, PGE2, iNOS and/or COX-2 genes or protein, which are factors associated with inflammation, and is additionally superbly effective for increasing and improving memory and the ability to learn, and thus can be beneficially used to prevent or treat neuroinflammation or neuro-degenerative diseases.

Abstract: Biologically active extract of Hibiscus tiliaceus L. and compositions containing the extract are described. Therapeutic uses of the extract and compositions include promoting healing of bone and cartilage injuries and also the promotion of bone and cartilage formation.

Abstract: The present invention relates to a plant extract from a low-tetrahydrocannabinol (THC) variety of Cannabis sativa subsp. sativa for the treatment of disease. The invention further relates to the production of the extract and pharmaceutical compositions comprising said extract and the uses thereof.

Abstract: Methods of treating a subject suffering from an ischemic condition and of preventing an ischemia-reperfusion injury in a subject suffering from an ischemic condition, particularly, but not exclusively ischemic heart disease and the subject is in particular a human, includes administering an effective amount of a carbohydrate composition extracted from Panax ginseng to the subject. The carbohydrate composition of the present invention extracted from Panax ginseng shows exceptional cardio-protective effect and, thus, provides a highly advantageous and highly promising treatment option for treatment of ischemic conditions and prevention of ischemia-reperfusion injury. The present invention further provides a method of protecting cells against hypoxia and reoxygenation induced cell death. Still further, the present invention provides a carbohydrate composition extracted from Panax ginseng and a pharmaceutical formulation comprising it.

Abstract: The present disclosure discloses a natural pharmaceutical composition for treating osteoporotic fracture and/or osteoarthritis and an application thereof. The composition is composed of 73.3 wt %-98.3 wt % of sea buckthorn pulp oil and 1.7 wt %-26.7 wt % of panax notoginseng saponins. The composition can be further used for preventing and treating ostealgia diseases.

Abstract: Provided is a method of treating or preventing adenovirus and enterovirus infection by administering an antiviral composition that contains an Echinacea purpurea extract, a Salvia miltiorrhiza extract, or combinations thereof. The antiviral composition blocks adenoviruses and enterovirus infection through virucidal activity against adenovirus and inhibition of adenovirus and enterovirus attachment to and penetration into cells. Also provided is a method of preparing the antiviral composition.

Abstract: I teach the processing and use of chemically extracted oil from the California Mugwart, Artemesia Douglasiana Besser. The topically applied extract prevents inflammation of poison oak or poison ivy, for example.

Abstract: A food composition arranged for human consumption comprising a plurality of ingredients, all from maca root. The invention provides a process for obtaining juice and powder from maca root, wherein the seed of maca root is grinded and centrifuged to make juice and powder. Total 837 protein found in maca root. Among them, 296 are uncharacterized and 35 are putative uncharacterized new found KH good healthy proteins synthesized by KH good healthy cells.

Abstract: A food composition arranged for human consumption comprising a plurality of ingredients, all from Mungbean. The invention provides a process for obtaining juice and powder from Mungbean, wherein the seed of Mungbean is grinded and centrifuged to make juice and powder. Total XXXX protein found in Mungbean. Among them, XXXX are uncharacterized and XXXX are putative uncharacterized new found KH good healthy proteins synthesized by KH good healthy cells.

Abstract: Disclosed is a method for enhancing the effect of an immunotherapy for cancer in a subject, comprising administering to the subject an effective amount of a polysaccharide extract of Astragalus membranaceus. Also disclosed is a method for increasing a subject's pool of M1 macrophages, wherein the subject is suffering from one or more conditions associated with undesirable M2 macrophage activation, the method comprising administering to the subject an effective amount of a polysaccharide extract of Astragalus membranaceus.

Abstract: In general, embodiments of the present invention essential oil animal treatment compositions, and methods of making and using such products and compositions. The compositions comprise an essential oil fraction include including oregano essential oil, thyme essential oil, and cinnamon essential oil. The compositions can optionally include one or more emulsifiers and be in the form of an emulsion. An emulsifier can include arabinogalactan. The use of these products and compositions can enhance the health and feed efficiency of animals.

Abstract: The present invention relates to novel black cumin extract compositions and a green process for making the composition. The black cumin extract composition of the invention can be used to treat anxiety, sleep and stress disorders along with significant effect on memory enhancement. The composition is available in oil and powder forms.

Abstract: Compositions and methods for treating and/or preventing hangover are disclosed. In certain embodiments, the compositions include at least one B vitamin, activated charcoal, magnesium, and at least one herbal extract.

Abstract: A first composition of essential oils, including 0.3% each of cedarwood, lavender, rosemary, thyme, and peppermint essential oils are thoroughly combined until evenly distributed. A second composition of oils are thoroughly combined, including 9.85% jojoba oil, 9.85% argan oil, and 78.79% grapeseed oil until evenly distributed. The first composition of essential oils is gradually stirred into the second composition of oils, producing a combined oil composition. The scalp is coated with the resulting combined oil composition, followed by massaging the oil composition into the scalp with kneading, squeezing and pinching motions, for 1-3 minutes and subsequently maintaining the oil mixture on the scalp for at least 30 minutes.

Abstract: A food composition for human consumption comprising a plurality of grape ingredients, wherein the plurality of grape ingredients comprise ground flesh, seed, stem, and skin from grapes, and wherein the plurality of grape ingredients further comprise a wine comprising one or more KH Wine proteins. Also, a food composition for human consumption comprising a plurality of pomace ingredients, wherein the plurality of pomace ingredients comprise ground flesh, seed, stem, and skin from pomace in grapes, and wherein the plurality of pomace ingredients further comprise one or more KH Pomace proteins. Further, a food composition for human consumption comprising a plurality of grape ingredients, wherein the plurality of grape ingredients comprise ground flesh, seed, stem, and skin from grapes, and wherein the plurality of grape ingredients further comprise one or more KH Grape proteins.

Abstract: Disclosed are compositions containing: a) Phaseolus vulgaris extract; b) Cynara scolymus extract; c) Echinacea angustifolia extract; d) Vitis vinifera extract and optionally e) Panax ginseng extract, mixed with suitable excipients.

Abstract: The invention is directed to peptides which inhibit phosphorylation of an amino phosphoacceptor domain of C/EBP? and their use for treating inflammation and fibrosis.

Abstract: The disclosure pertains to methods of treating or preventing a disease or condition associated with and/or induced by soluble A-beta oligomer such as Alzheimer's disease by administering to a subject in need thereof conformation specific and/or selective antibodies or binding fragments thereof and related products.

Abstract: The present invention relates to a composition that comprises the peptide QBP1 for use in the inhibition of memory consolidation, after a trauma, more preferably in Post-Traumatic Stress Disorder or related diseases.

Abstract: Disclosed are methods of treating kidney disease, infectious or inflammatory diseases, acute kidney injury and hypertension by administering a (pro)renin receptor (PRR) antagonist. In some instances the PRR antagonist is a polypeptide. The PRR antagonist can be a polypeptide having at least 70% identity to the amino acid sequence set forth in SEQ ID NO:2. Also disclosed are methods of decreasing proteinuria and methods of promoting wound healing by administering a PRR antagonist.

Abstract: The present invention provides a method for treating or ameliorating cerebrovascular diseases in a subject by using peptides isolated from extracts from rabbit skin inflamed by vaccinia virus. The present invention also provides a peptide comprising an amino acid sequence having at least 70% identity to SEQ ID NO: 1, or variants, mutants, derivatives, or fragments thereof.

Abstract: Provided herein are glycosylated peptide amphiphiles (GPAs), supramolecular glyconanostructures assembled therefrom, and methods of use thereof. In particular, provided herein are glycosaminoglycan (GAG) mimetic peptide amphiphiles (PAs) and supramolecular GAG mimetic nanostructures assembled therefrom that mimic the biological activities of GAGs, such as heparin, heparan sulfate, hyaluronic acid etc.

Abstract: The present invention relates to the use of an isolated nucleic acid molecule comprising a nucleotide sequence coding for a hyperpolarizing light-gated ion channel or pump gene from an archeon or for a light-active fragment of said gene, or the nucleotide sequence complementary to said nucleotide sequence, for treating or ameliorating blindness. The light-gated ion channel or pump gene can be a halorhodopsin gene.

Abstract: Nutritive polypeptides are provided herein. Also provided are various other embodiments including nucleic acids encoding the polypeptides, recombinant microorganisms that make the polypeptides, vectors for expressing the polypeptides, methods of making the polypeptides using recombinant microorganisms, compositions and formulations that comprise the polypeptides, and methods of using the polypeptides, compositions and formulations.

Abstract: Treatment with catestatin changes the proportion of two major phyla Bacteroidetes and Firmicutes in the gut microbiota in an opposite manner observed in intestinal disorders like IBD, IBS or non-intestinal disorders like obesity. Specifically, administration of an effective amount of catestatin increased the relative percentage of Bacteroidetes and decreased the relative percentage of Firmicutes in the gut microbiota.

Abstract: Provided herein are methods of treating beta-thalassemia by subcutaneous administration of about 0.8 mg/kg of an ActRII signaling inhibitor. Also provided herein are methods of adjusting the dose of the ActRII signaling inhibitor administered to the subject.

Abstract: A method of treating a patient who has gastric cancer, gastrointestinal cancer, colorectal cancer, pancreatic cancer, lung cancer, and/or renal cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has gastric cancer, gastrointestinal cancer, colorectal cancer, pancreatic cancer, lung cancer, and/or renal cancer. A method of treating a patient who has cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the cancer.

Abstract: The invention relates, in part, to methods and compositions that are useful to modulate metabolic function of cells in vivo or in vitro. In some aspects the invention includes methods and/or compositions that increase metabolism in cells, tissues, organs, and/or subjects. In certain aspects the invention includes methods and/or compositions useful to decrease metabolism in cells, tissues, organs, and/or in subjects.

Abstract: The present invention relates generally to the use of recombinant human CC10 (rhCC10), also known as recombinant human uteroglobin, for use as a therapeutic in the treatment of nasal rhinitis, nasal sinusitis, chronic rhinosinusitis, and nasal polyposis. More particularly, the invention provides methods, including broadly the critical dosage ranges of rhCC10 and intranasal route of administration, which may be administered to safely and effectively treat the aforementioned conditions. The invention further provides a composition useful in administering rhCC10 to humans.

Abstract: The present invention relates to binding proteins specific for VEGF-A, in particular to recombinant binding proteins comprising a polyethylene glycol moiety and a binding domain, which inhibits VEGF-Axxx binding to VEGFR-2. Examples of such recombinant binding proteins are proteins which comprise an ankyrin repeat domain with the desired binding specificity, and a polyethylene glycol moiety. The binding proteins are useful in the treatment of cancer and other pathological conditions, e.g. eye diseases such as age-related macular degeneration.

Abstract: Embodiments of the present invention provide for novel therapies, pharmaceutical compositions and methods for insulin independence utilizing a new optimized hamster Reg3 gamma peptide, which is new to the art and has not previously been considered for development in the 30 year history since its discovery. Methods, pharmaceutical compositions and therapies novel to the prior art are utilized in this invention to render patients with recent onset and existing type 1 diabetes insulin independent by an optimized hamster Reg3 gamma peptide and an immune tolerance agent for type 1 patients to become insulin independent and used alone without an immune tolerance agent for type 2 diabetes. While not wishing to be bound by theory, optimized Reg3 gamma peptides increases beta cell generation by its demonstrated properties shown within of transforming ductal pancreatic cells into new islets.

Abstract: Provided herein are compositions and methods for alleviating cancer or infection in a subject by administering a therapeutically effective amount of a pharmaceutical composition comprising an isolated PD-1 variant polypeptide. The PD-1 variant polypeptide can inhibit the activity of PD-1 by, for example, competitive or non-competitive inhibition of the interaction between wild-type PD-1 and one or more of its ligands, PD-L1 and PD-L2.

Abstract: The present invention relates to, inter alia, compositions and methods, including chimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity. In part, the invention provides, in various embodiments, fusions of extracellular domains of transmembrane proteins that can have stimulatory or inhibitory effects.

Abstract: The present invention relates generally to a method of treating a neoplastic condition. More particularly, the present invention is directed to a method of selectively sensitising neoplastic cells prior to chemotherapy. The method of the present invention is predicated on administering chemotherapy treatment subsequently to neoplastic cell sensitisation via the exposure of these cells to an activin type 1 B receptor (ACVR1B) antagonist. The present findings have now enabled the development of a new neoplastic treatment regime exhibiting both higher efficacy and reduced side effects for patients and, still further, a means of effectively treating chemoresistant neoplasms.

Abstract: The present disclosure provides, inter alia, formulation compositions comprising modified nucleic acid molecules which may encode a protein, a protein precursor, or a partially or fully processed form of the protein or a protein precursor. The formulation composition may further include a modified nucleic acid molecule and a delivery agent. The present invention further provides nucleic acids useful for encoding polypeptides capable of modulating a cell's function and/or activity.

Abstract: The present invention provides a modified chemokine peptide, comprising (a) an “ELR” characteristic sequence which is situated at the N-terminus of the modified chemokine peptide, (b) a “PASQF” characteristic sequence which is neighbored to the upstream of the third cysteine counted from N-terminus of the chemokine peptide, and (c) a modification at the 17th position counted from the N-terminus of the modified chemokine peptide. Additionally, the modified chemokine peptide can be used to treat cancer and inhibit tumor growth.